On July 14, 2025, Takeda Pharmaceutical Company reported that both Phase 3 studies of its drug Oveporexton (TAK-861) for treating Narcolepsy Type 1 met all primary and secondary endpoints, showing significant improvements in symptoms. The findings indicate a promising future for regulatory submissions and potential treatment approval.